Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Skye BioscienceFRA:09R -0.88%21 Net Debt Paydown Yield % is 5.14% as of Jul. 14, 2026. GuruFocus rates FRA:09R with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 1,160 Biotechnology companies, Skye Bioscience ranks better than 87.93% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Skye Bioscience's Net Debt Paydown Yield % was 5.14%.
Skye Bioscience (FRA:09R) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Skye Bioscience Net Debt Paydown Yield % Related Terms
Skye Bioscience Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Skye Bioscience's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:09R vs PLRZ, NEUP, LGVN: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Skye Bioscience's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Skye Bioscience Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Skye Bioscience's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Skye Bioscience's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 5.14% mean?
Skye Bioscience (FRA:09R) has a Net Debt Paydown Yield % of 5.14% as of Jul. 14, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Skye Bioscience and its competitors. According to the industry distribution chart, Skye Bioscience ranks #140 out of 1160 companies in the Biotechnology industry, placing it in the top 12.1%.
Is Skye Bioscience's Net Debt Paydown Yield % too high?
Skye Bioscience's current Net Debt Paydown Yield % is 5.14%. The Biotechnology industry median Net Debt Paydown Yield % is 0.04. Skye Bioscience's value of 5.14% is 14585.7% above this industry median. Based on the distribution chart, Skye Bioscience ranks #140 out of 1160 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Skye Bioscience has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's Net Debt Paydown Yield % compare to PLRZ and NEUP?
According to the Biotechnology industry distribution chart, Skye Bioscience ranks #140 out of 1160 companies for Net Debt Paydown Yield %. This places Skye Bioscience in the top 12% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.04. Skye Bioscience's value of 5.14% is 14585.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.04, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Skye Bioscience's current Net Debt Paydown Yield % of 5.14% is 14585.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Skye Bioscience and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Skye Bioscience's current Net Debt Paydown Yield % is 5.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R) has a current Net Debt Paydown Yield % of 5.14%. The current Net Debt Paydown Yield % is 5.14% and 14585.7% above the Biotechnology industry median of 0.04. Skye Bioscience's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Skye Bioscience (FRA:09R), the current Net Debt Paydown Yield % is 5.14% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
21GF Score
Get the complete analysis for FRA:09R
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:09R has been successfully added to your 
